Chinese medicinal composition for treating idiopathic thrombocytopenic purpura

Abstract

The invention relates to a Chinese medicinal composition for treating idiopathic thrombocytopenic purpura. The composition is prepared from the following raw material drugs in parts by weight: 6 to 12 parts of prepared rehmannia rhizome, 10 to 20 parts of raw rehmannia rhizome, 10 to 20 parts of figwort root, 9 to 15 parts of scutellaria baicalensis, 9 to 15 parts of cape jasmine, 9 to 15 parts of vietnamese sophora root, 10 to 15 parts of Chinese wolfberry root-bark, 30 to 60 parts of lalang grass rhizome, 10 to 20 parts of buffalo horn, 6 to 12 parts of rhizoma alismatis, 10 to 15 parts of cortex lycii radicis, 6 to 12 parts of Chinese angelica, 6 to 15 parts of peony bark, 10 to 15 parts of fructus forsythiae, 10 to 15 parts of dwarf lilyturf tuber, and 6 to 9 parts of liquorice. The Chinese medicinal composition has selected raw materials, reasonable compatibility, complementary functions and good synergy, can treat both principle and secondary aspect of a disease to idiopathic thrombocytopenic purpura, has relapse prevention after healing, stable curative effect, 95 percent of general effective rate, safe taking, low treatment cost, as well as small pain, drug resistance prevention and low toxic or side effect to a patient, and is easily accepted by patients.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura. Background technique [0002] Idiopathic thrombocytopenic purpura (abbreviated as ITP) is a clinical syndrome in which platelet destruction increases due to the immune mechanism, also known as autoimmune thrombocytopenic purpura (abbreviated as AITP), which is a relatively common bleeding disorder characterized by Peripheral thrombocytopenia, shortened platelet lifespan, normal or increased bone marrow megakaryocytes, accelerated platelet turnover rate. According to clinical manifestations, age of onset, duration of thrombocytopenia and treatment effect, it is divided into acute type and chronic type. The acute type is more common in children and is often self-limiting, while the chronic type is more common in young women. [0003] The vast majority of patients with chronic ...

AI Technical Summary

Problems solved by technology

[0004] After searching, the patent No. 200910075890.1 discloses a drug for treating allergic purpura. Yunling, Atractylodes macrocephala, Radix Paeoniae Rubra, Raw Glycyrrhizae and other components, the medicine has heat-clearing, cooling blood, blood stasis, hemostasis and anti-allergic effects, and can treat allergic purpura, but the curative effect on idiopathic thrombocytopenic purpura is not ideal. Therefore, it is necessary to develop a drug with ideal efficacy for the treatment of idiopathic thrombocytopenic purpura